Hartkamp 2004.

Methods	Double blind, controlled trial (Probably randomised but does not specify) 12 months
Participants	Total: 60 Sex: female Ethnicity: 82‐93% Caucasian Median age: 41‐45 years Inclusion criteria: quiescent SLE, on <10mg prednisolone Exclusion criteria: nil else
Interventions	Grp 1: DHEA 200mg/dy Grp 2: placebo
Outcomes	Stated primary: Wellbeing and fatigue (not reported) SLEDAI, Bone mineral density
Notes	Funding: Dutch Arthritis Association
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear